Anixa is harnessing the body's immune system in the fight against cancer.

By using the body’s immune system, Anixa Biosciences, Inc. is taking multiple approaches to fighting cancer—developing both diagnostics and therapeutics to detect cancer early, when it is most curable, and to treat those afflicted once diagnosed.


Diagnostics

We are developing the Cchek™ platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy.

Therapeutics

CAR-T

We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.

Breast Cancer Vaccine

We are developing a revolutionary breast cancer vaccine technology focused on treating as well as preventing triple negative breast cancer (TNBC), the most lethal form of the disease.

Sign up for email Updates

Be The First to Receive Breaking News

Sign Up Now
Logo Itus

Latest News & Events

Anixa Biosciences Provides Update on CAR-T Program

Read More...

Anixa Biosciences Announces Presentation at the 2019 San Antonio Breast Cancer Symposium

Read More...

Anixa Biosciences Announces Genesis Research to Join Cchek™ Prostate Cancer Study

Read More...

Stock Data

View Investors Relations
Nasdaq: ANIX
Price
Change

Cancer of the Lung, Breast, Colon, Prostate, and Stomach are the five most prevalent cancers worldwide.